Skip to content
10-K

Annual Report

MiNK Therapeutics, Inc. INKT

0001193125-26-134813

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 4.97M sh
Shares Diluted FY 2025 · Dec 31, 2025 4.27M sh
Shares Diluted FY 2025 · Dec 31, 2024 3.77M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$5.93M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$9.56M
Cash And Equivalents FY 2025 · Dec 31, 2025 $13.36M
Cash And Equivalents FY 2025 · Dec 31, 2024 $4.58M
Stockholders Equity FY 2025 · Dec 31, 2025 −$14.23M
Stockholders Equity FY 2025 · Dec 31, 2024 −$19.59M
Stockholders Equity FY 2025 · Dec 31, 2023 −$18.06M
Current Liabilities FY 2025 · Dec 31, 2025 $13.03M
Current Liabilities FY 2025 · Dec 31, 2024 $6.96M
Current Assets FY 2025 · Dec 31, 2025 $13.85M
Current Assets FY 2025 · Dec 31, 2024 $4.99M
Total Assets FY 2025 · Dec 31, 2025 $14.24M
Total Assets FY 2025 · Dec 31, 2024 $5.72M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.93
Eps Diluted FY 2025 · Dec 31, 2024 −$2.86
Eps Basic FY 2025 · Dec 31, 2025 −$2.93
Eps Basic FY 2025 · Dec 31, 2024 −$2.86
Sga Expense FY 2025 · Dec 31, 2025 $6.73M
Sga Expense FY 2025 · Dec 31, 2024 $4.31M
Rd Expense FY 2025 · Dec 31, 2025 $5.76M
Rd Expense FY 2025 · Dec 31, 2024 $6.34M
Net Income FY 2025 · Dec 31, 2025 −$12.49M
Net Income FY 2025 · Dec 31, 2024 −$10.78M
Operating Income FY 2025 · Dec 31, 2025 −$12.64M
Operating Income FY 2025 · Dec 31, 2024 −$11.29M